NasdaqGS - Nasdaq Real Time Price USD

Embecta Corp. (EMBC)

Compare
19.48
-0.77
(-3.80%)
At close: January 10 at 4:00:02 PM EST
19.48
0.00
(0.00%)
After hours: January 10 at 5:33:45 PM EST
Loading Chart for EMBC
DELL
  • Previous Close 20.25
  • Open 20.08
  • Bid 19.44 x 100
  • Ask 19.53 x 100
  • Day's Range 19.17 - 20.08
  • 52 Week Range 9.93 - 21.48
  • Volume 240,585
  • Avg. Volume 392,116
  • Market Cap (intraday) 1.132B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) 14.54
  • EPS (TTM) 1.34
  • Earnings Date Feb 7, 2025 - Feb 11, 2025
  • Forward Dividend & Yield 0.60 (4.16%)
  • Ex-Dividend Date Aug 27, 2024
  • 1y Target Est 21.05

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

www.embecta.com

2,200

Full Time Employees

September 30

Fiscal Year Ends

Recent News: EMBC

View More

Performance Overview: EMBC

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

EMBC
4.98%
S&P 500
1.35%

1-Year Return

EMBC
9.79%
S&P 500
22.51%

3-Year Return

EMBC
59.42%
S&P 500
24.59%

5-Year Return

EMBC
59.42%
S&P 500
77.94%

Compare To: EMBC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EMBC

View More

Valuation Measures

Annual
As of 1/10/2025
  • Market Cap

    1.13B

  • Enterprise Value

    2.47B

  • Trailing P/E

    14.54

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.01

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.20

  • Enterprise Value/EBITDA

    12.84

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.23%

  • Return on Assets (ttm)

    9.64%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    1.12B

  • Net Income Avi to Common (ttm)

    69.7M

  • Diluted EPS (ttm)

    1.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    275.1M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    46.59M

Research Analysis: EMBC

View More

Company Insights: EMBC

Research Reports: EMBC

View More

People Also Watch